(CYH) Community Health Systems - Overview
Stock: Hospital, Emergency, Surgery, Diagnostic, Outpatient, Virtual
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 65.2% |
| Relative Tail Risk | -11.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.15 |
| Alpha | -25.16 |
| Character TTM | |
|---|---|
| Beta | 1.192 |
| Beta Downside | 1.045 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.93% |
| CAGR/Max DD | -0.21 |
Description: CYH Community Health Systems December 27, 2025
Community Health Systems (CYH) operates a network of general acute-care hospitals across the United States, complemented by a broad suite of ancillary services that include emergency rooms, specialty surgeries, critical care, obstetrics, psychiatric care, rehabilitation, skilled-nursing facilities, home-care, and a growing portfolio of outpatient and virtual-health offerings. Founded in 1985 and headquartered in Franklin, Tennessee, the firm is classified under the Health Care Facilities sub-industry (GICS) and trades as common stock on the NYSE.
Key performance indicators that analysts typically monitor for CYH include: (1) **Adjusted EBITDA margin**, which hovered around 9-10 % in FY 2023, reflecting the capital-intensive nature of hospital operations; (2) **Occupancy rate**, averaging roughly 71 % across its hospital portfolio, a metric that is highly sensitive to regional population health trends and payer mix; and (3) **Debt-to-EBITDA**, standing near 5.5×, indicating elevated leverage relative to peers. Primary economic drivers for the sector are the aging U.S. demographic, which fuels demand for inpatient and post-acute services, and evolving Medicare/Medicaid reimbursement policies that can compress margins. Conversely, a slowdown in elective procedures or adverse changes in insurance coverage could materially impact revenue streams.
For a deeper quantitative assessment, you may explore ValueRay’s detailed CYH financial model.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 329.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.13 > 1.0 |
| NWC/Revenue: 8.07% < 20% (prev 7.82%; Δ 0.24% < -1%) |
| CFO/TA 0.04 > 3% & CFO 493.0m > Net Income 329.0m |
| Net Debt (11.12b) to EBITDA (1.40b): 7.94 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (135.0m) vs 12m ago 1.98% < -2% |
| Gross Margin: 33.95% > 18% (prev 0.41%; Δ 3354 % > 0.5%) |
| Asset Turnover: 93.16% > 50% (prev 90.27%; Δ 2.89% > 0%) |
| Interest Coverage Ratio: 1.19 > 6 (EBITDA TTM 1.40b / Interest Expense TTM 866.0m) |
Altman Z'' -0.16
| A: 0.08 (Total Current Assets 3.20b - Total Current Liabilities 2.18b) / Total Assets 13.24b |
| B: -0.28 (Retained Earnings -3.68b / Total Assets 13.24b) |
| C: 0.08 (EBIT TTM 1.03b / Avg Total Assets 13.57b) |
| D: -0.26 (Book Value of Equity -3.69b / Total Liabilities 14.19b) |
| Altman-Z'' Score: -0.16 = B |
Beneish M -2.83
| DSRI: 1.03 (Receivables 2.28b/2.19b, Revenue 12.64b/12.55b) |
| GMI: 1.22 (GM 33.95% / 41.33%) |
| AQI: 0.97 (AQ_t 0.36 / AQ_t-1 0.38) |
| SGI: 1.01 (Revenue 12.64b / 12.55b) |
| TATA: -0.01 (NI 329.0m - CFO 493.0m) / TA 13.24b) |
| Beneish M-Score: -2.83 (Cap -4..+1) = A |
What is the price of CYH shares?
Over the past week, the price has changed by -1.88%, over one month by -5.72%, over three months by -10.06% and over the past year by -7.40%.
Is CYH a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 4
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the CYH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.6 | 14.7% |
| Analysts Target Price | 3.6 | 14.7% |
| ValueRay Target Price | 2.9 | -8.3% |
CYH Fundamental Data Overview February 05, 2026
P/E Forward = 26.5252
P/S = 0.0347
P/EG = -1.64
Revenue TTM = 12.64b USD
EBIT TTM = 1.03b USD
EBITDA TTM = 1.40b USD
Long Term Debt = 10.59b USD (from longTermDebt, last quarter)
Short Term Debt = 126.0m USD (from shortTermDebt, last quarter)
Debt = 11.24b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.12b USD (from netDebt column, last quarter)
Enterprise Value = 11.56b USD (438.6m + Debt 11.24b - CCE 123.0m)
Interest Coverage Ratio = 1.19 (Ebit TTM 1.03b / Interest Expense TTM 866.0m)
EV/FCF = 80.82x (Enterprise Value 11.56b / FCF TTM 143.0m)
FCF Yield = 1.24% (FCF TTM 143.0m / Enterprise Value 11.56b)
FCF Margin = 1.13% (FCF TTM 143.0m / Revenue TTM 12.64b)
Net Margin = 2.60% (Net Income TTM 329.0m / Revenue TTM 12.64b)
Gross Margin = 33.95% ((Revenue TTM 12.64b - Cost of Revenue TTM 8.35b) / Revenue TTM)
Gross Margin QoQ = 8.55% (prev 42.67%)
Tobins Q-Ratio = 0.87 (Enterprise Value 11.56b / Total Assets 13.24b)
Interest Expense / Debt = 1.92% (Interest Expense 216.0m / Debt 11.24b)
Taxrate = 21.0% (US default 21%)
NOPAT = 815.3m (EBIT 1.03b * (1 - 21.00%))
Current Ratio = 1.47 (Total Current Assets 3.20b / Total Current Liabilities 2.18b)
Debt / Equity = -7.48 (negative equity) (Debt 11.24b / totalStockholderEquity, last quarter -1.50b)
Debt / EBITDA = 7.94 (Net Debt 11.12b / EBITDA 1.40b)
Debt / FCF = 77.76 (Net Debt 11.12b / FCF TTM 143.0m)
Total Stockholder Equity = -1.61b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.42% (Net Income 329.0m / Total Assets 13.24b)
RoE = -20.44% (negative equity) (Net Income TTM 329.0m / Total Stockholder Equity -1.61b)
RoCE = 11.49% (EBIT 1.03b / Capital Employed (Equity -1.61b + L.T.Debt 10.59b))
RoIC = 8.75% (NOPAT 815.3m / Invested Capital 9.32b)
WACC = 1.85% (E(438.6m)/V(11.68b) * Re(10.31%) + D(11.24b)/V(11.68b) * Rd(1.92%) * (1-Tc(0.21)))
Discount Rate = 10.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 1.13%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈143.0m ; Y1≈93.9m ; Y5≈42.8m
Fair Price DCF = N/A (negative equity: EV 1.36b - Net Debt 11.12b = -9.75b; debt exceeds intrinsic value)
EPS Correlation: 28.47 | EPS CAGR: -1.41% | SUE: 0.02 | # QB: 0
Revenue Correlation: 25.28 | Revenue CAGR: -1.22% | SUE: 2.61 | # QB: 4
EPS next Quarter (2026-03-31): EPS=-0.09 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.36 | Chg30d=+0.027 | Revisions Net=+0 | Growth EPS=-141.7% | Growth Revenue=+2.1%